First Manhattan’s Harvard Bioscience HBIO Stock Holding History

First Manhattan’s Portfolio HBIO Stock Details HBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-13,100	Closed	-$432K	–	1414
2017 Q4	$432K	Hold	13,100	–	–	﹤0.01%	572
2017 Q3	$491K	Hold	13,100	–	–	﹤0.01%	542
2017 Q2	$334K	Hold	13,100	–	–	﹤0.01%	590
2017 Q1	$340K	Hold	13,100	–	–	﹤0.01%	591
2016 Q4	$399K	Buy	13,100 +6,700	+105%	+$170K	﹤0.01%	542
2016 Q3	$174K	Buy	6,400 +2,000	+45%	+$55.5K	﹤0.01%	694
2016 Q2	$125K	Buy	+4,400	New	+$140K	﹤0.01%	768

Other funds holding HBIO

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

First Manhattan's HBIO Position: Q1 2018 in Review

First Manhattan sold out of Harvard Bioscience (HBIO) in Q1 2018, closing a stake of 13,100 shares — an estimated $432K sold.

First Manhattan first reported a position in HBIO in Q2 2016 and held it in 7 quarters. The position peaked at $491K in Q3 2017. 71 funds tracked by Wall St. Rank hold HBIO as of Q1 2018.

First Manhattan reported no remaining Harvard Bioscience position as of Q1 2018 after selling out during the quarter.
First Manhattan sold 13,100 Harvard Bioscience shares in Q1 2018, an estimated $432K.
First Manhattan first reported a position in Harvard Bioscience in Q2 2016 and held it in 7 quarters.
First Manhattan's Harvard Bioscience position peaked at $491K in Q3 2017.
71 funds tracked by Wall St. Rank held Harvard Bioscience as of Q1 2018.

Based on First Manhattan's 13F filing for Q1 2018, filed 20 Apr 2018.